Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Peroxisome Proliferator-Activated Receptor Agonists on Serum Inflammatory Markers in Diabetic Rats



Khazaei M1 ; Tahergorabi Z2 ; Salehi E1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Physiology, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran

Source: Journal of Isfahan Medical School Published:2014

Abstract

Background: Inflammation had a key role in several pathological conditions including atherosclerosis. Previous studies indicated that the proxisome proliferator-activated receptors (PPAR) are involved in numerous physiological and pathological conditions. The aim of this study was to investigate the effect of PPAR agonists including PPARα (fenofibrate), PPARβ/δ (GW0742), PPARγ (rosiglitazone) and pan PPAR (bezafibrate) administration on serum high-sensitive C-reactive protein (hsCRP) and interleukine-6 (IL-6) in male diabetic rats. Methods: The male Wistar rats were received streptozotocin for induction of type I diabetes. Then, they were randomly divided into five groups: diabetic, diabetic + fenofibrate (100 mg/kg/day; gavage), diabetic + GW0742 (1 mg/kg/day, subcutaneous), diabetic + rosiglitazone (8 mg/kg/day; gavage) and diabetic + bezafibrate (400mg/kg/day; gavage). After 21 days, the serum levels of hsCRP and IL-6 were measured using the enzyme-linked immunosorbent assay (ELISA) kits. Findings: Administration of different PPAR agonists did not alter serum hsCRP and IL-6 concentrations in diabetic animals. Conclusion: It seems that changes of serum inflammatory markers are not responsible for effects of PPARs agonist in atherosclerosis process and other mechanisms should be studied.
Other Related Docs